In The News
‘Considerable disquiet’: Pelvic mesh group members can challenge $405M settlements
Judge rejects sacked Super Retail Group execs’ settlement claims
$56M settlement approved in Monash IVF class action
Kids clothing retailer hit with $5M penalty for worker exploitation
Third person sentenced over $180M Courtenay House Ponzi scheme
Lawyerly holiday publishing schedule
Johnson & Johnson hit with class action over cold and flu medications
ASIC, Noumi win appeal in privilege fight over PwC report
‘In all circumstances unconscionable’: ASIC wins case against forex broker
Limitations defences not relevant to new claims in Victoria class actions, court told
Please login to bookmarkClose

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au